Secondary Myelodysplastic Syndromes (DBCOND0028569)

Identifiers

Synonyms

Myelodysplastic Syndromes, Secondary / Secondary Myelodysplastic Syndrome

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05292664	Venetoclax Basket Trial for High Risk Hematologic Malignancies	Asparaginase Erwinia chrysanthemi Azacitidine Calaspargase pegol Calcium Cortisone Cytarabine Dexamethasone Dexrazoxane Doxorubicin Hydrocortisone Hydrocortisone phosphate Hydrocortisone succinate Leucovorin Methotrexate Venetoclax Vincristine	treatment	1	recruiting
NCT00489203	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	Beclomethasone dipropionate Methotrexate Tacrolimus	supportive_care	2	completed
NCT00015990	Thalidomide in Treating Patients With Myelodysplastic Syndrome	Thalidomide	treatment	2	completed
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	Palifermin	supportive_care	Not Available	completed
NCT00118287	Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes	Azacitidine Etanercept	treatment	1 / 2	completed
NCT00002798	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Aldesleukin Asparaginase Escherichia coli Aspartic acid Busulfan Cyclophosphamide Cytarabine Daunorubicin Dexamethasone Etoposide Filgrastim Fludarabine Hydrocortisone Idarubicin Methotrexate Tioguanine	treatment	3	completed
NCT00095797	XK469R in Treating Patients With Refractory Hematologic Cancer	No drug interventions	treatment	1	completed
NCT01177371	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma	Busulfan Cyclophosphamide Cyclosporine Methotrexate Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT00118352	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT01305200	Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant	Calcium Phosphate	supportive_care	3	completed
NCT01083706	Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant	Azacitidine	treatment	2	completed
NCT00509249	Aflibercept in Treating Patients With Myelodysplastic Syndromes	Aflibercept	treatment	2	terminated
NCT01384513	A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies	Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT01839916	Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Therapeutic allogeneic lymphocytes	treatment	2	completed
NCT00045396	A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)	Tipifarnib	treatment	2	completed
NCT01093586	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Cyclosporine Methylprednisolone Methylprednisolone hemisuccinate Mycophenolate mofetil	treatment	2	completed
NCT00098826	SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes	Ispinesib	treatment	1	completed
NCT01529827	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Fludarabine Melphalan Methotrexate Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT00357162	Belinostat in Treating Patients With Myelodysplastic Syndromes	Belinostat	treatment	2	completed
NCT00104962	Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes	Lenalidomide	treatment	1	completed
NCT00445744	Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	Busulfan Cyclophosphamide Methotrexate Tacrolimus	treatment	Not Available	completed
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT00049504	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00459212	GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia	GTI-2040	treatment	1	completed
NCT01146210	Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia	No drug interventions	Not Available	Not Available	completed
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT02122081	Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Cyclophosphamide Methotrexate Tacrolimus	treatment	1	completed
NCT00450450	Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases	Filgrastim	treatment	3	completed
NCT00098423	Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes	Cytarabine Tanespimycin	treatment	1	completed
NCT00008177	Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT01044745	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Rituximab Tacrolimus	treatment	2	terminated
NCT00343798	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT00357305	Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders	Cytarabine Etoposide Vorinostat	treatment	1	completed
NCT00462605	MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia	Entinostat Sargramostim	treatment	2	completed
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT00112593	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Fludarabine Melphalan	treatment	Not Available	completed
NCT00309907	Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant	Etanercept Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT01175785	Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies	Cyclophosphamide Cyclosporine Dilanubicel Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT01567059	Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	2'-Deoxycytidine Cytarabine Decitabine Tosedostat	treatment	2	completed
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Filgrastim Plerixafor	treatment	Not Available	terminated
NCT00331513	Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes	Idarubicin Vorinostat	treatment	1	completed
NCT00369317	Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes	Asparaginase Escherichia coli Aspartic acid Cytarabine Daunorubicin Etoposide Tioguanine	treatment	3	completed
NCT00084916	CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase	Menthol Temsirolimus	treatment	2	completed
NCT00096122	Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia	Cytarabine Idarubicin Tipifarnib	treatment	1 / 2	completed
NCT00451048	Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia	Sunitinib	treatment	2	completed
NCT00119366	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	terminated
NCT00860574	Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia	Fludarabine Methotrexate Tacrolimus Treosulfan	treatment	2	completed
NCT00049582	Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia	2'-Deoxycytidine Decitabine	treatment	1	terminated
NCT00322101	Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia	Busulfan Cyclophosphamide Cyclosporine Fludarabine Methotrexate Mycophenolate mofetil Tacrolimus	treatment	3	completed
NCT00087204	Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	Becatecarin Rebeccamycin	treatment	1	completed
NCT00301769	SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia	SJG-136	treatment	1	terminated
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT02019069	CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Cytarabine Daunorubicin	treatment	2	completed
NCT01427881	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Busulfan Cyclophosphamide Cyclosporine Fludarabine	treatment	2	completed
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	withdrawn
NCT00475150	Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Cediranib	treatment	2	completed
NCT01041443	5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes	5-fluoro-2'-deoxycytidine Tetrahydrouridine	treatment	1	completed
NCT01812252	Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant	Azacitidine Decitabine	treatment	2	completed
NCT00351975	Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases	Azacitidine Belinostat	treatment	1	completed
NCT01168219	Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia	Aloe vera leaf Ascorbic acid Azacitidine Busulfan Fludarabine Glycerin Methopterin Methotrexate Nicotinamide Tacrolimus Vitamin A	treatment	2	completed
NCT00313586	Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	Azacitidine Entinostat	treatment	2	completed
NCT03333486	Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer	Cyclophosphamide Fludarabine	treatment	2	active_not_recruiting
NCT01757639	Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia	Ipilimumab	treatment	1	completed
NCT05379166	Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome	Azacitidine Venetoclax	treatment	2	recruiting
NCT03359460	Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome	Ibrutinib Lenalidomide	treatment	1	completed
NCT00588991	Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders	Carboplatin Topotecan Veliparib	treatment	1	active_not_recruiting
NCT02890329	Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	Decitabine Ipilimumab	treatment	1	active_not_recruiting
NCT01885689	Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia	Clofarabine Melphalan Sirolimus Tacrolimus	treatment	2	active_not_recruiting
NCT00101179	MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	Azacitidine Entinostat	treatment	1	completed
NCT03128359	High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant	Busulfan Cyclophosphamide Fludarabine Melphalan Mycophenolate mofetil Tacrolimus	supportive_care	2	completed
NCT02553941	Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome	Azacitidine Ibrutinib	treatment	1	completed
NCT02485535	Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant	Escitalopram Selinexor	treatment	1	completed
NCT01132586	Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia	Cytarabine Idarubicin Lenalidomide	treatment	1	completed
NCT00357565	Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia	Busulfan Cyclosporine Filgrastim Fludarabine Melphalan Mycophenolate mofetil	treatment	2	active_not_recruiting
NCT03630991	Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy	Edetate calcium disodium anhydrous Edetic acid Succimer	treatment	1	recruiting
NCT00105001	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Sirolimus Tacrolimus	treatment	2	completed
NCT00217646	Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	Sorafenib	treatment	1	completed